Health Care & Life Sciences » Biotechnology | Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. | Ownership

Companies that own Aptevo Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Dimensional Fund Advisors LP
1,351,656
5.98%
131,804
0%
06/30/2018
Renaissance Technologies LLC
1,149,400
5.09%
399,400
0.01%
06/30/2018
The Vanguard Group, Inc.
729,361
3.23%
-5,638
0%
06/30/2018
Sessa Capital IM LP
519,894
2.29%
-1,400,474
0.4%
06/30/2018
Park West Asset Management LLC
500,000
2.21%
315,371
0.11%
06/30/2018
Acadian Asset Management LLC
367,509
1.63%
162,218
0.01%
06/30/2018
BlackRock Fund Advisors
347,995
1.54%
2,313
0%
06/30/2018
D. E. Shaw & Co. LP
316,977
1.4%
33,351
0%
06/30/2018
JPMorgan Securities LLC (Investment Management)
290,313
1.29%
36,031
0%
06/30/2018
HighVista Strategies LLC
196,600
0.87%
196,600
0.48%
06/30/2018

About Aptevo Therapeutics

View Profile
Address
2401 4th Avenue
Seattle Washington 98121
United States
Employees -
Website http://aptevotherapeutics.com
Updated 07/08/2019
Aptevo Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics. Its pipeline includes Otlertuzumab, APVO414, APVO436, ROR1 Candidate, and ALG. APV-527.